Newron Pharmaceuticals
Market Cap
CHF95.7m
Last Updated
2020/04/01 00:41 UTC
Data Sources
Company Financials +
Executive Summary
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system in Italy and internationally.
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with adequate balance sheet.
Share Price & News
How has Newron Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NWRN's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
19.1%
NWRN
8.6%
CH Pharmaceuticals
5.2%
CH Market
1 Year Return
-42.2%
NWRN
-0.3%
CH Pharmaceuticals
-4.7%
CH Market
Return vs Industry: NWRN underperformed the Swiss Pharmaceuticals industry which returned -0.3% over the past year.
Return vs Market: NWRN underperformed the Swiss Market which returned -4.7% over the past year.
Shareholder returns
| NWRN | Industry | Market | |
|---|---|---|---|
| 7 Day | 19.1% | 8.6% | 5.2% |
| 30 Day | -1.3% | -0.3% | -6.3% |
| 90 Day | -15.6% | -6.2% | -12.7% |
| 1 Year | -42.2%-42.2% | 8.9%-0.3% | 0.08%-4.7% |
| 3 Year | -77.0%-77.0% | 33.8%15.2% | 15.8%4.0% |
| 5 Year | -82.1%-82.1% | 24.1%-0.8% | 18.3%-0.9% |
Price Volatility Vs. Market
How volatile is Newron Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Analysts Expect Breakeven For Newron Pharmaceuticals S.p.A. (VTX:NWRN)1 month ago | Simply Wall St
Here's What We Think About Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Pay2 months ago | Simply Wall St
Do Directors Own Newron Pharmaceuticals S.p.A. (VTX:NWRN) Shares?Valuation
Is Newron Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
2.46x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NWRN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate NWRN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NWRN is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: NWRN is unprofitable, so we can't compare its PE Ratio to the Swiss market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NWRN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NWRN is good value based on its PB Ratio (2.5x) compared to the CH Pharmaceuticals industry average (3x).
Next Steps
Future Growth
How is Newron Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
54.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NWRN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.6%).
Earnings vs Market: NWRN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: NWRN's is expected to become profitable in the next 3 years.
Revenue vs Market: NWRN's revenue (49% per year) is forecast to grow faster than the Swiss market (2.3% per year).
High Growth Revenue: NWRN's revenue (49% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NWRN's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Newron Pharmaceuticals performed over the past 5 years?
-2.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NWRN is currently unprofitable.
Growing Profit Margin: NWRN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NWRN is unprofitable, and losses have increased over the past 5 years at a rate of -2.6% per year.
Accelerating Growth: Unable to compare NWRN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NWRN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.9%).
Return on Equity
High ROE: NWRN has a negative Return on Equity (-54.91%), as it is currently unprofitable.
Next Steps
Financial Health
How is Newron Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: NWRN's short term assets (€59.9M) exceed its short term liabilities (€5.6M).
Long Term Liabilities: NWRN's short term assets (€59.9M) exceed its long term liabilities (€17.9M).
Debt to Equity History and Analysis
Debt Level: NWRN's debt to equity ratio (45.5%) is considered high.
Reducing Debt: NWRN's debt to equity ratio has increased from 3.7% to 45.5% over the past 5 years.
Balance Sheet
Inventory Level: NWRN has a low level of unsold assets or inventory.
Debt Coverage by Assets: NWRN's debt is covered by short term assets (assets are 3.6x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NWRN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NWRN has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of -12.6% each year.
Next Steps
Dividend
What is Newron Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NWRN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate NWRN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NWRN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NWRN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NWRN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
7.8yrs
Average management tenure
CEO
Stefan Weber (54yo)
7.75s
Tenure
€691,000
Compensation
Mr. Stefan Weber serves as the Chief Financial Officer and Finances and Administration Director at Duktus S.A. Mr. Weber has been the Chief Executive Officer of Newron Pharmaceuticals SpA since June 1, 201 ...
CEO Compensation Analysis
Compensation vs Market: Stefan's total compensation ($USD762.36K) is about average for companies of similar size in the Swiss market ($USD720.22K).
Compensation vs Earnings: Stefan's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 7.75yrs | €691.00k | 0.086% €82.3k | |
| Vice President of Finance | 7.75yrs | no data | 0.014% €13.4k | |
| Executive Vice President of Business Development | 7.75yrs | no data | no data | |
| Chief Medical Officer | 14.83yrs | €1.22m | 0.067% €64.5k |
7.8yrs
Average Tenure
62yo
Average Age
Experienced Management: NWRN's management team is seasoned and experienced (7.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 7.75yrs | €691.00k | 0.086% €82.3k | |
| Independent Non-Executive Director | 11.67yrs | €114.00k | no data | |
| Independent Non-Executive Chairman | 6.92yrs | €134.00k | 0.23% €215.7k | |
| Non-Executive Director | 6yrs | €109.00k | no data | |
| Member of Scientific & Clinical Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific and Clinical Advisory Board | no data | no data | no data | |
| Member of Scientific & Clinical Advisory Board | no data | no data | no data | |
| Member of Scientific & Clinical Advisory Board | no data | no data | no data | |
| Chairman of the Board of Statutory Auditors | 12.92yrs | €13.00k | no data |
8.2yrs
Average Tenure
58yo
Average Age
Experienced Board: NWRN's board of directors are considered experienced (8.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Newron Pharmaceuticals S.p.A.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Newron Pharmaceuticals S.p.A.
- Ticker: NWRN
- Exchange: SWX
- Founded: 1998
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CHF95.651m
- Shares outstanding: 17.85m
- Website: https://www.newron.com
Number of Employees
Location
- Newron Pharmaceuticals S.p.A.
- Via Ludovico Ariosto 21
- Bresso
- Milan
- 20091
- Italy
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| NWRN | SWX (SIX Swiss Exchange) | Yes | Ordinary Shares | CH | CHF | Dec 2006 |
| NP5 | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Dec 2006 |
| NWPH.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Dec 2006 |
| NP5 | XTRA (XETRA Trading Platform) | Yes | Ordinary Shares | DE | EUR | Dec 2006 |
| 0QOI | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | CHF | Dec 2006 |
Biography
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system in Italy and internationally. The company offers Xadago (safinamide) for the treatment of Parkinson’s disease. Its pipeline of products include Sarizotan for patients with Rett syndrome; Evenamide, a first add-on therapy for the treatment of patients with positive symptoms of schizophrenia; and Ralfinamide for patients with specific rare pain indications. Newron Pharmaceuticals S.p.A. has a collaboration agreement with Meiji Seika Pharma Co., Ltd. for the development and commercialization of safinamide in Japan and Asian territories. The company was founded in 1998 and is headquartered in Bresso, Italy.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/04/01 00:41 |
| End of Day Share Price | 2020/03/31 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.